Parallelly, as an FDA-approved small-molecule HIF-1α inhibitor, acrifavine inhibits tumor development by disrupting HIF-1α and HIF-1β dimer formation, inhibiting the transcriptional activity of HIF-1α, and down-regulating the expression of its downstream proteins VEGF and PGK-1, thereby inhibiting the signaling of downstream pathways. Here, HIF1A is linked to neoplasm.